Hepatitis A, B, and C Prevention Programs
Information and Programs for People at Risk
 
  Home
  Hep Express archives
    Search
 

Prevention Programs

  APIA programs
  Corrections, adult
  Corrections, juvenile
  Family planning
  Harm reduction
  Homeless programs
  MSM
  Perinatal related
  School programs
  STD/HIV
  Other programs
  Index of programs
    Support Group Info
  Hepatitis B
  Hepatitis C
  Listed by state
    Hepatitis B Info
  FAQ about hep B
  VISs
  Laws and mandates
  Case histories
  Photos
  Videos
    Hepatitis A Info
  FAQ about hep A
  VISs
  Laws and mandates
  Case histories
  Photos
    Hep-related Topics
  International adoption
  Tattooing and piercing
  Travel vaccination
  Healthcare workers
  Needle safety
  Dialysis
    Other Information
  CDC website
  Hep organizations
  NASTAD website
  Contact NASTAD
  About NASTAD
  Privacy policy
 

(click on the image)


Hep Express Issue 22

ABBREVIATIONS: ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention; DVH, Division of Viral Hepatitis; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; IAC, Immunization Action Coalition; IDU, injection drug user; MMWR, Morbidity and Mortality Weekly Report; MSM, men who have sex with men; STD, sexually transmitted disease; VIS, Vaccine Information Statement; WHO, World Health Organization.
----------------------------------------------------------------

(1 of 8)
October 13, 2004
CDC RELEASES HEPATITIS SURVEILLANCE REPORT NO. 59

In September, CDC issued a 54-page document "Hepatitis Surveillance Report No. 59." This publication summarizes viral hepatitis case reports received from state health departments. It is intended as a reference document for policy makers, program managers, health planners, researchers, and others who are concerned about the public health implications of viral hepatitis infection.

To read or download a copy in PDF format, go to:
http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/hep_surveillance_59.pdf
---------------------------------------------------------------
Return to top

(2 of 8)
October 13, 2004
CDC AND GACVS RESPOND TO NEUROLOGY ARTICLE ON HEPATITIS B VACCINE AND MULTIPLE SCLEROSIS

A recent article in the journal Neurology, "Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis: A Prospective Study," concluded that the findings of the study are consistent with the hypothesis that immunization with hepatitis B vaccine is associated with an increased risk of multiple sclerosis. However, CDC and WHO's Global Advisory Committee on Vaccine Safety (GACVS) do not agree with the conclusion of the study.

CDC concurs with the Neurology editorial accompanying the article that "the data presented do not provide proof of an association sufficient to implement policy changes with regard to immunization programs."

Read more in CDC's "Immunization Works":
http://www.cdc.gov/nip/news/newsltrs/imwrks/2004/200409.htm#other

GACVS "does not believe that the findings provide convincing support for the hypothesis that immunisation with recombinant hepatitis B vaccine is associated with an increased risk of multiple sclerosis." The Committee has prepared the following two responses:

World Health Organization Global Advisory Committee on Vaccine Safety: Response to the paper by MA Hernàn and others in Neurology 14th September 2004 issue entitled "Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis"
http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en

Questions and answers with respect to the recent study "Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis" published by Hernàn et al. in Neurology, 2004
http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/qa_sep04/en

To read the abstract of the original article on PubMed, click here.
----------------------------------------------------------------
Return to top

(3 of 8)
October 13, 2004
NEW TRANSLATION: "PROTECT YOURSELF AGAINST HEPATITIS A & B: A GUIDE FOR GAY AND BISEXUAL MEN" NOW AVAILABLE IN SPANISH

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 10/11/04.]

A Spanish-language version of IAC's two-page patient-education brochure "Protect Yourself against Hepatitis A and Hepatitis B . . . A Guide for Gay and Bisexual Men" is now available. Developed in April, the brochure educates men who have sex with men about their increased risk for contracting hepatitis A and hepatitis B and makes the case for getting immunized against them.

PLEASE NOTE: The brochure is intended for a gay audience in settings such as STD clinics and clinics for men who have sex with men. It is not intended for routine use in all clinic settings.

To access a ready-to-copy (PDF) version of the brochure in Spanish, go to:
http://www.immunize.org/catg.d/p4115-01.pdf

To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4115-01.htm

To access a ready-to-copy (PDF) version of the brochure in English, go to:
http://www.immunize.org/catg.d/p4115.pdf

To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4115.htm
----------------------------------------------------------------
Return to top

(4 of 8)
October 13, 2004
NEWLY REVISED HEPATITIS A VIS HAS BEEN TRANSLATED INTO SPANISH, CHINESE, AND TAGALOG

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 9/27/04.]

Dated 8/4/04, the current version of the VIS for hepatitis A vaccine is now available on the IAC website in Spanish, Chinese, and Tagalog. IAC gratefully acknowledges the California Department of Health Services for the translations.

To obtain a ready-to-copy (PDF) version of the VIS for hepatitis A vaccine in Spanish, go to:
http://www.immunize.org/vis/sp_hpa04.pdf

To obtain it in Chinese, go to:
http://www.immunize.org/vis/ch_hpa04.pdf

To obtain it in Tagalog, go to:
http://www.immunize.org/vis/ta_hpa04.pdf

To obtain it in English, go to:
http://www.immunize.org/vis/v-hepa.pdf

For information about the use of VISs, and for VISs in a total of 32 languages, visit IAC's VIS web section at http://www.immunize.org/vis
----------------------------------------------------------------
Return to top

(5 of 8)
October 13, 2004
IAC REVISES THREE PATIENT EDUCATION BROCHURES RELATED TO VIRAL HEPATITIS

IAC recently updated the following three brochures:

  1. "Hepatitis A Is a Serious Liver Disease."
    Written in Q&A format, the brochure was expanded to include more questions. In addition, new graphics give the brochure a fresh, contemporary look.
     
    To access a ready-to-copy (PDF) version of the updated brochure, go to:
    http://www.immunize.org/catg.d/p4080a.pdf 
    To access a web-text (HTML) version, go to:
    http://www.immunize.org/catg.d/p4080a.htm
     

  2. "Hepatitis A & B: Be sure your patient gets the correct dose!"
    The sheet lists various brands of hepatitis A vaccine, hepatitis B vaccine, and combination vaccines that contain either vaccine or both. It outlines the recommended dosages and dosing schedules for children, adolescents, and adults. The primary change was to extend the range of the second adult dose of Merck & Co.'s Vaqta hepatitis A vaccine from 6-12 months to 6-18 months.
     
    To access a ready-to-copy (PDF) version of the revised sheet, go to:
    http://www.immunize.org/catg.d/2081ab.pdf 
    To access a web-text (HTML) version of it, go to:
    http://www.immunize.org/catg.d/2081ab.htm
     

  3. "If you, your parents, or your children were born in any of these places . . . give this brochure to your health care provider and ask to find out your hepatitis B status"
    This brochure encourages persons from HBV-endemic areas to know their hepatitis B status, get vaccinated if susceptible to HBV infection, and obtain medical care if infected. Information about hepatitis B treatment was changed from the earlier version.
     
    To access a ready-to-copy (PDF) version of the revised brochure, go to:
    http://www.immunize.org/catg.d/p4170ref.pdf
    To access a web-text (HTML) version of it, go to:
    http://www.immunize.org/catg.d/p4170.htm

----------------------------------------------------------------
Return to top

(6 of 8)
October 13, 2004
CDC OFFERS EXPANDED WEB RESOURCES ON HEPATITIS C AND INJECTION DRUG USE

CDC's Division of Viral Hepatitis offers a variety of online resources to help prevent hepatitis C virus infection in injecting drug users. Resources include specialized fact sheets, links to related organizations, and a ready-to-copy brochure for injecting drug users created by the Academy for Educational Development and the National Minority AIDS Council.

CDC estimates that injection drug use accounts for 60% of all new cases of hepatitis C and is a major risk factor for infection with hepatitis B virus.

Visit the Injection Drug Use web section at
http://www.cdc.gov/ncidod/diseases/hepatitis/c/index.htm#idu
----------------------------------------------------------------
Return to top

(7 of 8)
October 13, 2004
NATIONAL ASSOCIATION OF HEPATITIS TASK FORCES LAUNCHES WEBSITE

On September 13, 2004, the National Association of Hepatitis Task Forces (NAHTF) announced the launch of a new website. NAHTF provides support for developing and existing community hepatitis task forces.

To visit the website, go to: http://www.nahtf.org
----------------------------------------------------------------
Return to top

(8 of 8)
October 13, 2004
NOVEMBER 19 IS THE DEADLINE FOR ABSTRACTS FOR CDC'S 2005 NATIONAL IMMUNIZATION CONFERENCE

[The following is cross posted from the Immunization Action Coalition's "IAC EXPRESS" electronic newsletter, 10/04/04.]

November 19 is the deadline for submitting abstracts for CDC's 2005 National Immunization Conference, which will be held in Washington, DC, on March 21-24, 2005. The deadline for early-bird registration ($150) is January 28. The deadline for regular registration ($175) is March 4.

Abstracts must be submitted online. To access submission guidelines, go to: http://www.cdc.gov/nip/nic/#abstract For general conference information, including conference goals and objectives and registration, go to: http://www.cdc.gov/nip/nic

For additional information, contact the conference planning team at (404) 639-8225 or nipnic@cdc.gov


Nastad
www.nastad.org
nastad@nastad.org
          Hepatitis Prevention Programs
www.hepprograms.org
nastad@nastad.org

444 North Capitol Street, NW • Suite 339 • Washington D.C. 20001 • (202) 434-8090